Real-world data vital to advancing cancer research according to recent survey
- The study of 200 practicing oncologists in the United States also found that oncologists believe it is important for all clinical trials to include a real-world data component, and the overwhelming majority (78 percent) would urge pharmaceutical companies and cancer research groups to use real-world data in all clinical trials
- The study also highlighted a few particular areas where oncologists’ perceptions differed from that of patients’ and from industry realities, including:need for more diversity in cancer clinical trials, a growing patient expectation for better cancer treatments, faster
- “The (COVID-19) pandemic highlighted the vital benefit real-world data can have when it comes to ensuring the efficacy and safety of swiftly developed vaccines aimed at decreasing the impact of COVID-19, … It is not surprising that providers and patients now want to see the same turnaround time for cancer drugs and treatments. Real-world data is one solution to this challenge of speeding cancer-specific innovation.“
C.K. Wang, MD, Chief Medical Officer at COTA, Inc.
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.